VMAT-IGRT Hypofractionated Radiotherapy for Locally Advanced Thyroid Cancer in Resource-Limited Settings: A Retrospective Report from Bolivia

Abstract

This study evaluated the efficacy and safety of hypofractionated external beam irradiation with VMAT-IGRT in patients with locally advanced thyroid cancer (LATC) who are ineligible for surgery or I-131 in a resource-limited setting such as Bolivia. Thirty-three patients were treated with H-VMAT-IGRT between August 2018 and November 2022. Axial CT images were acquired every 3 mm from the base of the skull to the middle of the chest. GTV was determined based on contrast-enhanced tumor on T1 MRI or CT scans. CTV 55 Gy at 2.75 Gy was defined based on visible residual tumor and included dissected nodal stations with pathologically positive nodes. CTV 44 at 2.2 Gy for non-dissected nodal stations with low risk of recurrence, we escalated the dose up to 60 Gy at 3 Gy for small tumors up to 20 cc. PTVs were created by adding a 0.3 cm margin around CTVs, with a reduced margin of minus 3-5 mm for critical organs such as esophagus, pharynx, and brachial plexus. Equivalent dose in 2Gy (EQD2 10-3) was reported for tumor control and OAR constraints. Acute toxicity was reported according to RTOG criteria, and response to treatment was assessed at baseline, end of treatment, and every third month thereafter. The mean time since last follow-up was 24 months (r: 8-40). Patients were 80% female and 20% male. The mean age was 50 years (r: 29-72). Local recurrence was treated in 52% (13) of patients and LATC in 48% (12). Papillary carcinomas accounted for 68% of patients, followed by anaplastic (24%) and follicular (8%) carcinomas. Tumors were classified according to the AJCC classification. Of the patients treated for LATC, 25% were at stage II, 25% at stage III, 16.67% at stage IVA, and 33.33% at stage IVB. Among patients treated for local recurrence, the initial stage before progression was stage I in 61.5%, stage II in 30.8%, and stage IVA in 7.7%. The median PTV was 383.8 cc (r: 51.7 - 627.3) and the median CTV55 was 189.2 cc (r: 39.6 - 519.8). Grade 1 (10%), Grade 2 (90%) dysphagia, Grade 1 (40%), Grade 2 (60%) acute pharyngeal mucositis, and no Grade 3 acute toxicity were observed. No reports of chronic upper damage GI, 30% xerostomia G2. Two-year local control was 70% and overall survival was also 70%. We suggest that reducing treatment duration while maintaining efficacy is particularly beneficial in resource-limited areas with a shortage of trained personnel and overburdened treatment centers. We report good local control rates with no detrimental effects on quality of life with hypofractionation. No evidence of delayed damage, such as spinal cord dysfunction, mandibular osteoradionecrosis, or brachial plexopathy, was noted. We emphasize the importance of using VMAT with IGRT for reliable and accurate daily treatment of the target area, while minimizing side effects. However, these results should be confirmed with a larger sample of patients.